Understanding how certain proteins affect blood clotting issues caused by heparin.
The role of proteoglycans in Heparin-induced thrombocytopenia: Implications for pathophysiology, diagnosis and treatment
This study is looking at how certain proteins in your blood might play a role in heparin-induced thrombocytopenia (HIT), a serious condition that can happen if you’re treated with heparin, and it aims to find out how different factors like age, sex, and ethnicity affect this condition to help improve tests and treatments for patients at risk.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11010341 on NIH RePORTER |
What this research studies
This research investigates the role of specific proteins called proteoglycans in the development of heparin-induced thrombocytopenia (HIT), a serious condition that can occur in patients receiving heparin. The study aims to identify the platelet components that interact with heparin and trigger the immune response leading to HIT. By analyzing differences in these components based on factors like age, sex, and ethnicity, the research seeks to improve diagnostic tests and treatment strategies for affected patients. This could lead to better risk stratification and targeted therapies for those at higher risk of developing HIT.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients who are receiving heparin and may be at risk for developing heparin-induced thrombocytopenia.
Not a fit: Patients who are not receiving heparin or those who have not experienced any adverse reactions to heparin are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnosis and treatment options for patients suffering from heparin-induced thrombocytopenia.
How similar studies have performed: Previous research has shown promise in identifying biomarkers for HIT, but this study aims to explore novel aspects of the condition that have not been extensively tested.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Kanack, Adam J — Mayo Clinic Rochester
- Study coordinator: Kanack, Adam J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.